Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine

Go back to Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
Marina Biotech, Inc. (NASDAQ: MRNA) Delayed: 58.07 --0 (-0%)
Previous Close $58.07    52 Week High $0.52 
Open $58.07    52 Week Low $0.08 
Day High $58.07    P/E N/A 
Day Low $58.07    EPS $-3.80 
Volume 11,212